How does emerging patent case law in the US and Europe affect precision medicine? How will today’s patent law affect tomorrow’s innovation in the areas of biomarkers and nature-based products; diagnostics; and algorithms, big data and AI?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Mateo Aboy, Glenn Cohen, Kathleen Liddell, Johnathan Liddicoat, Cristina Crespo, Sara Gerke, Timo Minssen

Precision medicine has stirred the excitement of patients, physicians, industry, entrepreneurs, and investors — it is already a market that is worth tens of billions of dollars with very rapid growth expected. But the future of
precision medicine heavily depends on the intellectual property frameworks that apply to its various forms. In order to chart this future, we compare recent patent case law in the US and Europe in three areas of precision medicine: (1) biomarkers and nature-based products; (2) diagnostics; and (3) algorithms, big data, and AI. We explain how today’s law will affect tomorrow’s innovation.
OriginalsprogEngelsk
TidsskriftNature Biotechnology
Vol/bind37
Udgave nummer10
Sider (fra-til)1118–1125
Antal sider8
ISSN1087-0156
DOI
StatusUdgivet - 2 okt. 2019

ID: 213793813